Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 January 2013

 

London, UK (January 18, 2013) – This page provides an overview of the opinions adopted at the January 2013 meeting of the CHMP and other important outcomes. In the table below, readers can view the main opinions adopted at the meeting, as well as information on referral procedures. The new public-health communication document on Agency’s recommendation to suspend Tredaptive, Pelzont and Trevaclyn combines the press release and question-and-answer document previously published following CHMP meetings. The Agency publishes a new page following the CHMP meeting each month.

 


Positive recommendations on new medicines

 

Name of medicine

Bosulif

International non-proprietary name (INN)

bosutinib

Marketing-authorisation applicant

Pfizer Ltd

Therapeutic indication

Treatment of chronic myelogenous leukaemia

More information

Summary of opinion for Bosulif

 

Name of medicine

Jetrea

INN

ocriplasmin

Marketing-authorisation applicant

ThromboGenics NV

Therapeutic indication

Treatment of symptomatic vitreomacular adhesion

More information

Summary of opinion for Jetrea

Press release: European Medicines Agency recommends approval of medicine for treatment of vitreomacular traction

 

 

Negative recommendation on new medicine

 

Name of medicine

Raxone

INN

idebenone

Marketing-authorisation applicant

Santhera Pharmaceuticals (Deutschland) GmbH

Therapeutic indication

Treatment of Leber’s hereditary optic neuropathy

More information

Questions and answers on the refusal of the marketing authorisation for Raxone

 

 

Positive recommendations on new generic medicines

 

Name of medicine

Actelsar HCT

INN

telmisartan / hydrochlorothiazide

Marketing-authorisation applicant

Actavis Group PTC

Therapeutic indication

Treatment of essential hypertension

More information

Summary of opinion for Actelsar HCT

 

Name of medicine

Maruxa

INN

memantine

Marketing-authorisation applicant

Krka dd Novo mesto

Therapeutic indication

Treatment of Alzheimer’s disease

More information

Summary of opinion for Maruxa

 

Name of medicine

Tolucombi

INN

telmisartan / hydrochlorothiazide

Marketing-authorisation applicant

Krka dd Novo mesto

Therapeutic indication

Treatment of essential hypertension

More information

Summary of opinion for Tolucombi

 

 

Positive recommendations on extensions of therapeutic indications

 

Name of medicine

Humira

INN

adalimumab

Marketing-authorisation holder

Abbott Laboratories Ltd

Change to a therapeutic indication
(changes in bold)

Polyarticular juvenile idiopathic arthritis

Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Humira has not been studied in children aged less than 2 years.


Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

More information

Summary of opinion for Humira

 

Name of medicine

Ilaris

INN

canakinumab

Marketing-authorisation holder

Novartis Europharm Ltd

Therapeutic indication
(changes in bold)

Cryopyrin-associated periodic syndromes


Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) in adults, adolescents and children aged 2 years and older with body weight of 7.5 kg or above, including:
– Muckle-Wells syndrome (MWS),
– Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA), severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.

Gouty arthritis:
Ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate (see section 5.1).

More information

Summary of opinion for Ilaris

 

Name of medicine

Komboglyze

INN

saxagliptin / metformin hydrychloride

Marketing-authorisation holder

Bristol-Myers Squibb

Therapeutic indication
(changes in bold)

Komboglyze is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.

Komboglyze is also indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control.

Komboglyze is also indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus when the maximally tolerated dose of both metformin and the sulphonylurea does not provide adequate glycaemic control.

More information

Summary of opinion for Komboglyze

 

Name of medicine

Onglyza

INN

saxagliptin

Marketing-authorisation holder

Astra Zeneca EEIG

Therapeutic indication
(changes in bold)

Onglyza is indicated in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control:

as dual oral therapy in combination with
– metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control.
– a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control. in patients for whom use of metformin is considered inappropriate.
– a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate.

as triple oral therapy in combination with
– metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control


as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

More information

Summary of opinion for Onglyza

 

Name of medicine

Pegasys

INN

peginterferon alfa-2a

Marketing-authorisation holder

Roche Registration Ltd

New indication

Paediatric patients 5 years of age and older:

Pegasys in combination with ribavirin is indicated for the treatment of chronic hepatitis C in treatment-naïve children and adolescents 5 years of age and older, who are positive for serum HCV-RNA.

When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).


Detailed conditions for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

More information

Summary of opinion for Pegasys



 

Outcome of arbitration procedure

 

Name of medicine

Kantos Master and associated names

INN

beclometasone dipropionate / formoterol fumarate

Marketing-authorisation holder

Chiesi Farmaceutici S.p.A

More information

Questions and answers on Kantos Master and associated names

Withdrawals of applications

 

Name of medicine

Loulla

INN

mercaptopurine

More information

Questions and answers on the withdrawal of the marketing authorisation application for Loulla

 

Name of medicine

Memantine FGK

INN

memantine

More information

Questions and answers on the withdrawal of the marketing authorisation application for Memantine FGK

Public-health communication

 

European Medicines Agency confirms recommendation to suspend Tredaptive, Pelzont and Trevaclyn

Other updates

 

Opinions on annual re-assessments, renewals of marketing authorisations and accelerated assessment procedures

Opinions on safety variations

Start of community reviews

Scientific advice and protocol assistance

Guidelines and concept papers adopted

Overview of invented names reviewed in January 2012 by the Name Review Group (NRG)

Organisational matters

 

 


European Medicines Agency (EMA), 18.01.2013 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 
Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung